ArticlePloS one2025
Evaluation of GDH and HDP as novel serological biomarkers for Plasmodium falciparum malaria diagnosis across varying parasitemia and transmission settings in India.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malaria diagnosis has progressed significantly with the introduction of Rapid Diagnostic Tests (RDTs) targeting Histidine-Rich Protein 2 (HRP2), Lactate dehydrogenase (LDH), and aldolase. However, challenges remain, such as the presence of Plasmodium falciparum histidine-rich protein 2 (pfhrp2) gene deletions and reduced sensitivity in regions with low parasitemia. This study evaluates antibody responses to novel biomarkers-glutamate dehydrogenase (GDH) and Heam detoxification protein (HDP)-in comparison to conventional antigens (HRP2, LDH, and aldolase) across different infection, transmission settings, and parasitemia conditions. We analyzed plasma samples from 928 participants, including 886 P. falciparum-positive cases, using enzyme-linked immunosorbent assay. Our results revealed antibody levels against all studied peptides clear differentiation between malaria-positive and negative samples, with Receiver Operating Characteristic (ROC) curve analysis showing high diagnostic accuracy (Area under the ROC curve > 96%) for detecting P. falciparum infection. However, the sensitivity and specificity for differentiating between endemicity or parasitemia groups were limited for certain peptides. Specifically, GDH2 and HRP2 effectively distinguished parasitemia levels, while GDH2, HDP2, and LDH showed promise in distinguishing between varying endemicity levels. These findings suggest that GDH and HDP have significant potential as reliable serological biomarkers for malaria detection. However, further studies are needed to refine their application in categorizing endemicity and parasitemia. This research highlights the need for adaptable diagnostic tools to address the complex challenges of malaria in endemic regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.